HomeMVR0 • FRA
add
Medivir AB
Previous close
€0.14
Day range
€0.12 - €0.13
Year range
€0.00010 - €0.21
Market cap
864.03M SEK
Avg Volume
268.00
P/E ratio
-
Dividend yield
-
Primary exchange
STO
Market news
Financials
Income Statement
Revenue
Net income
| (SEK) | Dec 2025info | Y/Y change |
|---|---|---|
Revenue | 5.50M | 522.17% |
Operating expense | 37.60M | 402.61% |
Net income | -43.20M | -62.30% |
Net profit margin | -785.45 | 73.91% |
Earnings per share | — | — |
EBITDA | -11.80M | 55.59% |
Effective tax rate | — | — |
Balance Sheet
Total assets
Total liabilities
| (SEK) | Dec 2025info | Y/Y change |
|---|---|---|
Cash and short-term investments | 119.20M | 90.63% |
Total assets | 306.40M | 77.53% |
Total liabilities | 41.90M | -26.59% |
Total equity | 264.50M | — |
Shares outstanding | 448.67M | — |
Price to book | 0.24 | — |
Return on assets | -48.36% | — |
Return on capital | -61.34% | — |
Cash Flow
Net change in cash
| (SEK) | Dec 2025info | Y/Y change |
|---|---|---|
Net income | -43.20M | -62.30% |
Cash from operations | -6.30M | 78.56% |
Cash from investing | — | — |
Cash from financing | 102.00M | 17,214.09% |
Net change in cash | 95.70M | 418.08% |
Free cash flow | -22.38M | 6.40% |
About
Medivir is a Swedish biotech company. Medivir focuses its research focus on oncology and particularly on innovative pharmaceuticals that meet substantial unmet medical needs. The pharmaceutical development work is conducted both in-house and through partnerships, usually with global pharmaceutical companies.
Medivir has a leading expertise in the design of protease inhibitors and in the science of nucleotides and nucleosides.
Medivir is listed on the Nasdaq Stockholm Mid Cap List.
In February 2020, Medivir announced that the company has signed a licensing agreement for Xerclear with Chinese company Shijiazhuang Yuanmai Biotechnology Co Ltd. The agreement gives SYB the right to register, manufacture and market the product in China. Wikipedia
Founded
1988
Website
Employees
10
